MetaCap

Artiva Biotherapeutics Inc. (ARTV)

NASDAQ: ARTVHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

3.78-0.05 (-1.31%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ARTV stock chart

Technical analysis

Key statistics

All statistics
Market cap
$186.85M
EPS (TTM)
-$2.85
52-week range
2.96 – 14.53
Day range
3.77 – 3.93
Volume / Avg
1.78M / 792.26K
Beta
—

52-week range

$2.96$14.53

ARTV stock today

Artiva Biotherapeutics (ARTV) closed at $3.78 on Nov 20, down 1.31% (-$0.05), versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 1.78M shares, a sign of unusually heavy trading. Shares are 74.0% below their 52-week high of $14.53, set on Apr 20, 2026 and 27.7% above the 52-week low of $2.96, near the bottom of the past year's range.

ARTV is down 11.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 20.8%. Artiva Biotherapeutics has posted a net loss over the last twelve months (EPS of -$2.85), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Artiva Biotherapeutics

Company profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Fred Aslan M.D.
Headquarters
San Diego, CA
Employees
134
IPO year
2024

Financial highlights

Full financials

In fiscal 2025, Artiva Biotherapeutics generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Artiva Biotherapeutics reported a net loss of $83.9 million, compared with a loss of $65.4 million a year earlier. Diluted earnings per share came in at -$3.43.

Artiva Biotherapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$0$251.00K$33.49M
Growth-100.00%-99.25%—
Net income$-83.86M$-65.37M$-28.72M
EPS (diluted)$-3.43$-5.81$-35.78

Analyst forecast

Forecast

Consensus (6 analysts)

buy

Avg. price target

$20.75+448.94%

  • Strong buy 0
  • Buy 2
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $40.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.56 vs $-0.54
Surprise
-3.70%

ARTV news

All ARTV news

Artiva Biotherapeutics peers

Health Care sector
ARTV peer companies
CompanyPrice% ChgMarket capCompare
IKTInhibikase Therapeutics Inc.1.32+1.54%$185.16Mvs ARTV
LCTXLineage Cell Therapeutics Inc.0.7719-5.87%$195.26Mvs ARTV
CABACabaletta Bio Inc.0.9361-7.32%$201.94Mvs ARTV
CGENCompugen Ltd.1.84-2.13%$174.29Mvs ARTV
IPSCCentury Therapeutics Inc.1.17-11.74%$211.56Mvs ARTV
ALLOAllogene Therapeutics Inc.0.6277-5.88%$217.48Mvs ARTV
PALIPalisade Bio Inc.0.8399-9.24%$150.74Mvs ARTV
SCTXScribe Therapeutics Inc.12.07-8.70%$228.58Mvs ARTV

Indexes, lists and sector

Artiva Biotherapeutics stock FAQ

What is Artiva Biotherapeutics's stock price today?

ARTV last traded at $3.78 as of Nov 20, 4:00 PM EST, down 1.31% on the day. Prices are delayed at least 15 minutes.

Who is Artiva Biotherapeutics's CEO?

Dr. Fred Aslan M.D. is the chief executive officer of Artiva Biotherapeutics Inc., which has about 134 employees.

What is the ARTV 52-week high?

The 52-week high for ARTV is $14.53 and the 52-week low is $2.96. The stock is currently 74.0% below its high.

Compare ARTV